VRTX Q1 2020 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$125B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.5B+76.5% YoY

Gross Profit

$1.4B89.3% margin

Operating Income

$720M47.5% margin

Net Income

$603M39.8% margin

EPS (Diluted)

$2.29

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$816M

Free Cash Flow

$796M

Stock-Based Comp.

$116M

Balance Sheet

Total Assets

$8.9B

Total Liabilities

$2.4B

Stockholders' Equity

$6.5B

Cash & Equivalents

$3.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.5B	$858M	+76.5%
Gross Profit	$1.4B	$763M	+77.2%
Operating Income	$720M	$277M	+160.2%
Net Income	$603M	$269M	+124.4%

Revenue Segments

TRIKAFTA/KAFTRIO

$895M59%

ORKAMBI

$234M15%

KALYDECO

$213M14%

SYMDEKO/SYMKEVI

$173M11%

Geographic Segments

UNITED STATES

$1.2B78%

Europe

$257M17%

Other, Non U.S.

$70M5%